Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Ultimovacs

Ultimovacs
2011 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
ULTIMO STOCK SYMBOL
1 INVESTMENTS
$3.32 SHARE PRICE (As of Friday Closing)
Description

Ultimovacs ASA is a Norway based pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
OSL
Primary Office
  • Ullernchausséen 64
  • 0379 Oslo
  • Norway

+47 413 00 000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ultimovacs’s full profile, request a free trial.

Ultimovacs Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.21 - $4.00 $92.4M $3.32 -$0.24 6.43K 27.9M

Ultimovacs Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 90,753
Revenue 0 0 0 0
EBITDA (5,732) (6,869) (3,974) (3,414)
Net Income (5,678) (6,788) (3,970) (3,448)
Total Assets 61,093 21,792 21,777 9,558
Total Debt 430
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ultimovacs Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Ultimovacs‘s full profile, request access.

Request full access to PitchBook

Ultimovacs Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 03-Sep-2018 0000000000 00.000 Drug Discovery 0000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

Ultimovacs Subsidiaries (1)

Company Name Industry Location Founded
00000000 Drug Discovery Uppsala, Sweden 0000
To view this company’s complete subsidiary history, request access »

Ultimovacs Executive Team (7)

Name Title Board
Seat
Contact
Info
Øyvind Kongstun Arnesen MD Chief Executive Officer
Hans Eid Chief Financial Officer
Audun Tornes Chief Operating Officer
Sara Mangsbo Ph.D Chief Development Officer
Gustav Gaudernack Chief Scientific Officer

1 Former Executive

You’re viewing 5 of 7 executives. Get the full list »

Ultimovacs Board Members (9)

Name Representing Role Since Contact
Info
00000 00000000 000000 Self Board Member 000 0000
00ø00 00000000 Gjelsten Holding Board Member 000 0000
000000 000ü00000 Gjelsten Holding Board Member 000 0000
00000 000000000 00 Self Board Member 000 0000
00000 000000000 Ultimovacs Chairman 000 0000
You’re viewing 5 of 9 board members. Get the full list »